RecruitMe Clinical Trial
A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Study for patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma using study drug pembrolizumab
| Sponsor: | Merck |
| Enrolling: | Male and Female Patients |
| Age Range: | Between 18 and 99 years old |
| IRB Number: | AAAO8259 |
| U.S. Government ID: | NCT02335411 |
| Contact: | Gulam Manji, MD: 646-317-6085 / gam2140@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to assess the safety, tolerablility, and effectiveness of pembrolizumab alone or in combination with standard treatment (cisplatin and 5-fluorouracil) for recurrent or metastatic Gastric Cancer or Gastroesophageal Junction Cancer. Participants will be in the study for approximately 24 months.
This study is closed
